Teva Introduces AUSTEDO XR as FDA Approves New Treatment Option

Wednesday, 29 May 2024, 19:48

Teva's announcement of the FDA approval for AUSTEDO XR, an extended-release tablet for therapeutic doses, offers a convenient once-daily treatment option. Patients can now benefit from the simplicity and effectiveness of a single pill to manage their condition with doses ranging from 24 to 48 mg/day.

https://store.livarava.com/807ac1b3-1e0e-11ef-a3e5-9d5fa15a64d8.jpg — Teva Introduces AUSTEDO XR as FDA Approves New Treatment Option

Teva Announces AUSTEDO XR FDA Approval

Teva has received FDA approval for AUSTEDO XR, an extended-release tablet for clinically therapeutic doses of 24-48 mg/day. This new once-daily treatment option offers convenience and efficacy for patients managing their conditions.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.